Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

141. A meta-analysis of the association between Toxoplasma gondii infection and epilepsy

A meta-analysis of the association between Toxoplasma gondii infection and epilepsy Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2018 PROSPERO

142. Technology in epilepsy care and self-management: hermeneutic review

Technology in epilepsy care and self-management: hermeneutic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures

2018 PROSPERO

143. Psychiatric co-morbidity among people with epilepsy in Sub-Saharan Africa a systematic review and meta-analysis

Psychiatric co-morbidity among people with epilepsy in Sub-Saharan Africa a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

144. The effects of stem cells therapy on seizure control in animal models of epilepsy - a systematic review and meta-analysis of preclinical studies

The effects of stem cells therapy on seizure control in animal models of epilepsy - a systematic review and meta-analysis of preclinical studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

145. Association of HMGB1 levels with epilepsy: a systematic review and meta-analysis

Association of HMGB1 levels with epilepsy: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2018 PROSPERO

146. Clonazepam monotherapy for treating people with newly diagnosed epilepsy [Cochrane protocol]

Clonazepam monotherapy for treating people with newly diagnosed epilepsy [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2018 PROSPERO

147. Epilepsy associated with risk of sexual dysfunction (SD) in both sexes: a systematic review and meta-analysis

Epilepsy associated with risk of sexual dysfunction (SD) in both sexes: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2018 PROSPERO

148. Knowledge of and attitudes towards epilepsy among teachers: a systematic review

Knowledge of and attitudes towards epilepsy among teachers: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2018 PROSPERO

149. Diagnosis and management of epilepsy in adults

Diagnosis and management of epilepsy in adults SIGN 143 • Diagnosis and management of epilepsy in adults A national clinical guideline Evidence May 2015 · Revised 2018KEY TO EVIDENCE STATEMENTS AND GRADES OF RECOMMENDATIONS LEVELS OF EVIDENCE 1 ++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1 + Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 1 - Meta-analyses, systematic reviews, or RCTs with a high risk of bias (...) in the web version of this document, which is the definitive version at all times. This version can be found on our web site www.sign.ac.uk. This document is produced from elemental chlorine-free material and is sourced from sustainable forests.Scottish Intercollegiate Guidelines Network Diagnosis and management of epilepsy in adults A national clinical guideline Revised 2018Scottish Intercollegiate Guidelines Network Gyle Square, 1 South Gyle Crescent Edinburgh EH12 9EB www.sign.ac.uk First published

2018 SIGN

150. The impact of insufficient sleep on seizure frequency in epilepsy patients: a systematic review of longitudinal studies

The impact of insufficient sleep on seizure frequency in epilepsy patients: a systematic review of longitudinal studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

151. Risk factors for epilepsy with mental disease: a meta-analysis

Risk factors for epilepsy with mental disease: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing

2018 PROSPERO

152. Comparisons of direct and indirect health utility measures in adult epilepsy: a systematic review

Comparisons of direct and indirect health utility measures in adult epilepsy: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2018 PROSPERO

153. Comparison of direct and indirect health utility measures in childhood epilepsy: systematic review

Comparison of direct and indirect health utility measures in childhood epilepsy: systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2018 PROSPERO

154. Efficacy of the modified Atkins diet in patients with refractory epilepsy

Efficacy of the modified Atkins diet in patients with refractory epilepsy Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2018 PROSPERO

155. Clinical Commissioning Policy: Deep Brain Stimulation for Refractory Epilepsy

Clinical Commissioning Policy: Deep Brain Stimulation for Refractory Epilepsy NHS England » Clinical Commissioning Policy: Deep Brain Stimulation for Refractory Epilepsy (all ages) Search Search Menu Clinical Commissioning Policy: Deep Brain Stimulation for Refractory Epilepsy (all ages) Document first published: 2 March 2018 Page updated: 2 March 2018 Topic: , Publication type: This policy document outlines the arrangements for funding of Deep Brain Stimulation for Refractory Epilepsy

2018 NHS England

156. Study suggests that pre-existing maternal epilepsy increases the risk of adverse perinatal outcomes

Study suggests that pre-existing maternal epilepsy increases the risk of adverse perinatal outcomes Study suggests that pre-existing maternal epilepsy increases the risk of adverse perinatal outcomes | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Study suggests that pre-existing maternal epilepsy increases the risk of adverse perinatal outcomes Article Text Commentary Women’s health & midwifery Study suggests that pre-existing maternal epilepsy

2018 Evidence-Based Nursing

157. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Full Text available with Trip Pro

Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Epilepsy is a common neurological condition with a worldwide prevalence of around 1%. Approximately 60% to 70% of people with epilepsy will achieve a longer-term remission from seizures, and most achieve that remission shortly after starting antiepileptic drug treatment. Most people with epilepsy are treated with a single antiepileptic drug (monotherapy) and current guidelines from the National (...) AEDs (carbamazepine, phenytoin, sodium valproate, phenobarbitone, oxcarbazepine, lamotrigine, gabapentin, topiramate, levetiracetam, zonisamide) currently used as monotherapy in children and adults with partial onset seizures (simple partial, complex partial or secondary generalised) or generalised tonic-clonic seizures with or without other generalised seizure types (absence, myoclonus).We searched the following databases: Cochrane Epilepsy's Specialised Register, CENTRAL, MEDLINE and SCOPUS

2017 Cochrane

158. Stiripentol (Diacomit) - for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet syndrome)

Stiripentol (Diacomit) - for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet syndrome) Final Appraisal Recommendation Advice No: 2617 – November 2017 Stiripentol (Diacomit ® ) 250 mg and 500 mg hard capsules; 250 mg and 500 mg powder for oral suspension in sachet Resubmission by Biocodex Additional note(s): • AWMSG considered that stiripentol (Diacomit ® (...) (where available) and the lay member perspective. This recommendation has been ratified by Welsh Government and will be considered for review every three years. Recommendation of AWMSG Stiripentol (Diacomit ® ) is recommended for use within NHS Wales for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet syndrome) whose seizures are not adequately controlled

2017 All Wales Medicines Strategy Group

159. Psychological treatments for people with epilepsy. Full Text available with Trip Pro

Psychological treatments for people with epilepsy. Given the significant impact epilepsy can have on the health-related quality of life (HRQoL) of individuals with epilepsy and their families, there is great clinical interest in evidence-based psychological treatments, aimed at enhancing psychological well-being in people with epilepsy. A review of the current evidence was needed to assess the effects of psychological treatments for people with epilepsy on HRQoL outcomes, in order to inform (...) future therapeutic recommendations and research designs.To assess the effects of psychological treatments for people with epilepsy on HRQoL outcomes.We searched the following databases on 20 September 2016, without language restrictions: Cochrane Epilepsy Group Specialized Register, CENTRAL, MEDLINE PsycINFO, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform (ICTRP). We screened the references from included studies and relevant reviews, and contacted researchers in the field

2017 Cochrane

160. Histopathological Findings in Brain Tissue Obtained during Epilepsy Surgery. Full Text available with Trip Pro

Histopathological Findings in Brain Tissue Obtained during Epilepsy Surgery. Detailed neuropathological information on the structural brain lesions underlying seizures is valuable for understanding drug-resistant focal epilepsy.We report the diagnoses made on the basis of resected brain specimens from 9523 patients who underwent epilepsy surgery for drug-resistant seizures in 36 centers from 12 European countries over 25 years. Histopathological diagnoses were determined through examination (...) of the specimens in local hospitals (41%) or at the German Neuropathology Reference Center for Epilepsy Surgery (59%).The onset of seizures occurred before 18 years of age in 75.9% of patients overall, and 72.5% of the patients underwent surgery as adults. The mean duration of epilepsy before surgical resection was 20.1 years among adults and 5.3 years among children. The temporal lobe was involved in 71.9% of operations. There were 36 histopathological diagnoses in seven major disease categories. The most

2017 NEJM